Sharp at CES 2020: Realizing an 8K+5G Ecosystem
6.1.2020 02:03:00 EET | Business Wire | Press release
Sharp Corporation (TOKYO:6753) is set to return to CES 2020 with an exhibit showcasing the latest installments in its evolving ecosystem of products and services that leverage the benefits of Ultra-HD 8K video and advanced 5G wireless technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200105005022/en/
(Graphic: Business Wire)
Sharp’s 8K+5G Ecosystem comprises end-to-end solutions for the recording, editing, storage, and delivery of 8K content, with potential benefits extending far beyond entertainment and broadcasting to such diverse fields as industry, security, health, education, automotive, smart offices, and smart homes. One much-anticipated addition to a constantly expanding portfolio of 8K products and services is the new dynabook 8K video editing PC system, which with its 15.6-inch screen will provide a compact, convenient, prosumer-ready platform for the viewing and processing of 8K materials.
Meanwhile, striking examples of Sharp’s 8K+5G Ecosystem on display at CES 2020 will include a drone-mounted system developed in conjunction with various external stakeholders for the real-time capture and transmission of 8K footage for purposes including racehorse training and infrastructure surveys. It’s one of various cross-disciplinary collaborations currently undergoing trials in order to bring the practical benefits of 8K and 5G directly to businesses and consumers.
“Collaborations are a pillar of our efforts to leverage the benefits of 8K+5G,” says Bob Ishida, Executive Vice President and Head of ICT Group. “We are conducting trials with a range of external partners, all with the aim of realizing a comprehensive 8K+5G ecosystem as soon as possible. And as our CES 2020 exhibit will show, we firmly believe that, in conjunction with the introduction of 5G, our 8K technology can make a major contribution to the society of the future.”
Learn more about Sharp at CES 2020: https://global.sharp/brand/globalevents/ces2020/
About Sharp
Sharp Corporation is a worldwide developer of innovative products and core technologies that play a key role in shaping the future of electronics. Sharp sets its business vision as “Changing the World with 8K+5G and AIoT.” 8K technology creates images that reveal a world beyond our everyday reality and gives birth to thrilling new discoveries. AIoT connects people and society through artificial intelligence and IoT technology. Being the origin of countless innovations, through these ideas, Sharp will continue to revolutionize the world. Sharp Corporation employs 52,640 people around the world (as of September 30, 2019) and recorded consolidated annual sales of 2.4 trillion yen for the fiscal year ended March 31, 2019.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200105005022/en/
Contact information
Sharp Corporation
PR/Branding Team
pr-brand@sharp.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom